Valacyclovir Hydrochloride
A to Z Drug Facts
Valacyclovir Hydrochloride |
(val-lay-SIGH-kloe-vihr HIGH-droe-KLOR-ide) |
Valtrex |
Tablets: 500 mg |
Tablets: 1 g |
Class: Anti-infective, Antiviral |
Action Converted to acyclovir, which then inhibits viral DNA replication by interfering with viral DNA polymerase.
Indications Treatment of herpes zoster (shingles); treatment or suppression of genital herpes; treatment of herpes labialis (cold sores).
Contraindications Hypersensitivity or intolerance to valacyclovir, acyclovir, or any component of the formulation.
Herpes Zoster
Adults: PO 1 g tid for 7 days (initiate therapy within 48 hr of onset of rash).
Genital Herpes
Adults: PO Initial episodes: 1 g bid for 10 days (initiate therapy within 48 to 72 hr of onset of signs and symptoms). Recurrent episodes: 500 mg bid for 3 days (initiate therapy within 24 hr of onset of signs or symptoms). Suppressive therapy: 1 g once daily. If history of recurrence up to 9 recurrences/yr, 500 mg/day may be administered.
Herpes Labialis
Adults: PO 2 g bid for 1 day approximately 12 hr apart, initiated at earliest symptoms of cold sore (eg, tingling, burning, itching).
Cimetidine, probenecid:
Increased acyclovir serum concentrations.
Lab Test Interferences None well documented.
CNS: Headache; dizziness. GI: Nausea; vomiting; diarrhea; constipation; abdominal pain; anorexia. OTHER: Asthenia.
Pregnancy: Category B. Lactation: Undetermined (acyclovir is excreted in breast milk). CHILDREN: Safety and efficacy not established. Elderly: Dosage reduction may be necessary, depending on underlying renal status. Renal function impairment: Dosage reduction may be necessary; exercise caution when giving valacyclovir to patients with renal impairment or those receiving potentially nephrotoxic drugs. Immunocompromised: Valacyclovir is not indicated for use in immunocompromised patients.
PATIENT CARE CONSIDERATIONS |
|
Herpes Zoster
Genital Herpes
Books@Ovid
Copyright © 2003 Facts and Comparisons
David S. Tatro
A to Z Drug Facts